Table 2.
Health-related quality of life outcomes from the European Organization of Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire measures at 6 months after surgery for gastroesophageal junction adenocarcinoma of Siewert type II or III
| Gastrectomy n = 47 |
Esophagectomy n = 101 |
Esophagogastrectomy n = 28 |
Esophagectomy vs. gastrectomy | Esophagogastrectomy vs. gastrectomy | |
|---|---|---|---|---|---|
| Mean score (95% CI) | Mean score (95% CI) | Mean score (95% CI) | Mean score difference | Mean score difference | |
| Global status | |||||
| Global quality of life | 54 (47–62) | 63 (57–69) | 59 (49–69) | 8 | 5 |
| Functions | |||||
| Physical | 75 (68–81) | 77 (72–82) | 72 (63–80) | 2 | 3 |
| Role | 58 (47–68) | 66 (58–75) | 56 (42–70) | 9 | 2 |
| Emotional | 69 (62–76) | 73 (68–79) | 71 (61–80) | 4 | 2 |
| Cognitive | 75 (68–82) | 85 (79–90) | 84 (75–93) | 10a | 9 |
| Social | 69 (60–78) | 72 (65–79) | 61 (49–73) | 3 | −8 |
| Symptoms | |||||
| Fatigue | 49 (41–57) | 41 (34–47) | 50 (39–61) | −8 | 1 |
| Nausea/vomiting | 25 (18–33) | 24 (18–30) | 16 (6–25) | −1 | −10a |
| Pain | 27 (18–36) | 24 (17–31) | 21 (9–33) | −3 | −6 |
| Dyspnea | 25 (15–35) | 30 (22–38) | 37 (24–50) | 5 | 12* |
| Insomnia | 26 (17–36) | 25 (17–32) | 20 (8–32) | −2 | −6 |
| Appetite loss | 41 (29–52) | 39 (30–48) | 46 (31–61) | −2 | 5 |
| Constipation | 10 (3–17) | 14 (9–20) | 10 (1–19) | 4 | 0 |
| Diarrhea | 31 (21–41) | 27 (19–36) | 22 (8–35) | −4 | −9 |
| Financial problems | 13 (6–21) | 14 (8–20) | 11 (1–21) | 1 | −2 |
Data are presented as adjusted mean scores and 95% confidence intervals (CI) and mean score differences. Clinically significant differences (mean score difference of >10 scores) between comparison groups are bolded
a Rounded value, not clinically significant
* p = 0.114, chi-squared test